China geographic atrophy market size and trajectory — the emerging commercial market for GA diagnosis and treatment reflecting both the enormous patient population and the recent therapeutic breakthrough creating the first-ever treatment options — represents a nascent but commercially significant market, with the China Geographic Atrophy Market reflecting the market's scale and growth potential.

Market size — currently pre-commercial treatment phase in China (no NMPA-approved GA treatment as of 2024) but diagnostic market (OCT, FAF imaging) estimated at approximately RMB 500 million to one billion for GA-specific imaging services. The treatment market anticipated to emerge approximately two to four years post-NMPA approval reaching estimated RMB two to four billion by 2030 with appropriate NHSA reimbursement.

Patient population commercial foundation — the estimated five to eight million Chinese GA patients representing the world's largest GA patient pool from China's 300-plus million elderly population. Even modest diagnosis rate improvement from baseline creates the substantial patient volumes that commercial GA treatment markets require.

Future commercial development pathway — NMPA application submission (anticipated from Apellis and Astellas after NMPA engagement), Phase III China-specific data generation or bridging study, NMPA approval (anticipated two to four years post-US), NHSA price negotiation for NRDL inclusion, commercial launch with physician education, and progressive diagnosis rate improvement — collectively creating the commercial market development timeline toward a multi-billion RMB GA treatment market in China.

Do you think the China GA treatment market will be commercially significant by 2030, or will NMPA approval timelines and reimbursement challenges delay meaningful commercial development?

FAQ

What is the current and projected China GA market size? China GA market current state: no NMPA-approved treatment (2024); diagnostic market: OCT and FA imaging for GA approximately RMB 500 million-1 billion annually (patients getting diagnosis and monitoring); treatment market: pre-commercial; projected treatment market: NMPA approval anticipated 2026-2028 (optimistic); NHSA inclusion: additional two to three year negotiation; commercial launch: realistically 2027-2030; market size at commercialization: estimated RMB 1-3 billion by 2030 (dependent on diagnosis rate improvement and pricing); long-term potential: RMB 5-10 billion+ if diagnosis rates improve toward developed market levels; comparison: wet AMD China market approximately RMB 3-5 billion (with established treatments and reimbursement).

What key events will shape the China GA commercial market through 2030? Key China GA market events: NMPA application filing (expected 2024-2025 from Apellis/Astellas); Phase III data in Chinese patients (bridge study or China-specific); NMPA approval decision (2026-2028 realistic); NHSA pharmacoeconomic assessment; NHSA annual negotiation and NRDL inclusion (approximately one to two years post-approval); commercial launch with physician education; diagnosis rate improvement from commercial awareness campaigns; patient adherence programs; competition: multiple complement inhibitors and potential gene therapy programs; domestic Chinese GA therapeutic program development; 2030 milestone: established GA treatment market with NHSA coverage and growing patient access.

#ChinaGeographicAtrophy #ChinaGAmarket #GeographicAtrophyChina #GAtreatmentChina #ChineseGAsize #RetinalMarketChina